Samsung Biologics Reports Fourth Quarter Fiscal Year 2022 Financial Results
- Written by PR Newswire
- Q4'22 consolidated revenue of KRW 965.5 billion and Q4'22 operating profit of KRW 312.8 billion.
- FY'22 consolidated revenue of KRW 3.00 trillion and FY'22 operating profit of KRW 983.6 billion.
- Strong growth momentum expected to continue with active expansions in capacity, geography, and portfolio.
INCHEON, South Korea, Jan. 27, 2023 /PRNewswire/...
Read more: Samsung Biologics Reports Fourth Quarter Fiscal Year 2022 Financial Results














